Leahy, M.

patient treatment cancer group response cisplatin study nutlin m-cavi grade toxicity phase sarcoma chemotherapy trial survival cycle nutlin -3 grade 3 oncology progression month tumour therapy mdm 2 inhibition oncology information downloaded result gemcitabine disease non-gist group m-cavi arm firmed society combination american society bajorin risk groups bajorin gc arm european tissue table cisplatin-based chemotherapy tissue sarcoma response rate effect death wild-type analysis reason non-gist apoptosi caspase carcinoma erasmus mc gist group agent /carboplatin firmed uncon firmed medische bibliotheek urothelial nutlin -3 treatment activity inhibition tumours methotrexate factor caspase -3 bladder nccit brostallicin 2102 ep inhibitor wild-type p 53 number bajorin risk factors research oncol 2102 ep cells bladder cancer information